APPLICATIONS
Foundation models for the decisions that shape a cancer drug.
Clyra turns cross-species cancer biology into patient-subgroup and biomarker hypotheses designed to support oncology development.
FIRST COMMERCIAL APPLICATION
Which biologically distinct patient subgroups are hidden inside the overall study population?
Potential outputs: Integrated molecular subgroup map · Survival-linked patient segments · Biological interpretation of subgroup differences · Prioritized retrospective and prospective validation hypotheses
Trial enrichment
Can a more biologically defined population produce a clearer clinical signal?
Potential outputs: Candidate enrichment hypotheses · Subgroup-specific outcome analysis · Patient-selection rationale · Validation requirements for future trial design
Drug positioning
Where does an asset have the strongest biological and clinical-development rationale?
Potential outputs: Mechanism-linked tumor states · Indication or subgroup hypotheses · Response heterogeneity interpretation · Evidence gaps and validation priorities
Response and resistance
What separates benefit, non-response, recurrence, and resistance?
Potential outputs: Response-associated tumor states · Resistance pathways and microenvironment hypotheses · Longitudinal state transitions · Biomarker candidates for further validation
PLATFORM EXPANSION
One foundation. Multiple oncology decisions.
As Clyra’s data and models expand across cancer types, therapies, and outcomes, the same foundation can support broader response modeling, therapeutic strategy, and target discovery. These are platform expansion opportunities, not currently validated commercial products.
Discuss a Program